Dr. Hans Klingemann, pioneering immunotherapy scientist, has studied whether the innovative treatment could save his two pets.

Immunotherapy has transformed cancer treatment. It tinkers with the immune system to attack malignancies that have evaded the body’s natural defenses. This advance offers an alternative to treating cancer with surgery or chemotherapy and radiation, which can attack healthy tissue and cause extreme side effects.

The treatment is not only scientifically complex but also expensive. The investment of money and time makes sense when it comes to saving humans. But what about when it comes to dogs?

Dr. Hans Klingemann has worked on and researched cancer immunotherapy for decades, leading departments at Rush University Medical Center in Chicago and Tufts Medical Center in Boston. Now, he’s the chief science officer for cellular products at ImmunityBio, which develops immunotherapy drugs for people. But he has also written two papers exploring whether the new treatments might someday prolong canine lives.

The interview below has been condensed and edited for clarity.

What interests you about immunotherapy and dogs?

I love dogs. I have dogs: Sophie and Maximilian. They are each around 18 pounds, a mix of a bichon and a Cavalier spaniel.

Did they develop cancer?

Fortunately, they haven’t gotten cancer…. yet. But when dogs get older, many get cancer. Are there some benefits from immunotherapy? Could we make life easier, the remaining life, for the dog and the owner?

We are having trouble retrieving the article content.

Please enable JavaScript in your browser settings.


Thank you for your patience while we verify access. If you are in Reader mode please exit and log into your Times account, or subscribe for all of The Times.


Thank you for your patience while we verify access.

Already a subscriber? Log in.

Want all of The Times? Subscribe.